Network-guided prediction of aromatase inhibitor response in breast cancer.
Matthew RuffaloRoby ThomasJian ChenAdrian V LeeSteffi OesterreichZiv Bar-JosephPublished in: PLoS computational biology (2019)
Prediction of response to specific cancer treatments is complicated by significant heterogeneity between tumors in terms of mutational profiles, gene expression, and clinical measures. Here we focus on the response of Estrogen Receptor (ER)+ post-menopausal breast cancer tumors to aromatase inhibitors (AI). We use a network smoothing algorithm to learn novel features that integrate several types of high throughput data and new cell line experiments. These features greatly improve the ability to predict response to AI when compared to prior methods. For a subset of the patients, for which we obtained more detailed clinical information, we can further predict response to a specific AI drug.
Keyphrases
- estrogen receptor
- gene expression
- artificial intelligence
- high throughput
- end stage renal disease
- machine learning
- single cell
- ejection fraction
- newly diagnosed
- dna methylation
- papillary thyroid
- big data
- deep learning
- prognostic factors
- electronic health record
- emergency department
- healthcare
- squamous cell
- breast cancer risk
- adverse drug